Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Greenwich LifeSciences, Inc.

GLSI · Nasdaq · CIK 0001799788 · Healthcare · Biotechnology

INSIDER SIGNAL

40.0 / 100

1 buyers · 5 purchase transaction lines · $97.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+7.4 / 25
Role+13.0 / 20
Recency+2.6 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: CEO and CFO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Patel SnehalCEO and CFO
●●●●●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Patel Snehal · $97.0K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-07-23–2026-07-29

Roles in the peak window: CEO and CFO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

40.0 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 40.3
  2. 40.2
  3. 40.2
  4. 40.1
  5. 40.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

13Purchases
0Sales
0Other Form 4 lines
11SEC filings · 365 days
BUYING5 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+9.8%
3M
-11.0%
6M
-35.9%
12M
+44.4%

Volatility & liquidity

Volatility
82.1%
Beta
—
Avg daily value
USD 2.3M

Valuation

Market cap
USD 242.6M
P/E
—

Fundamentals

Profit margin
—
ROE
-5480.5%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-24 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,580,950
Previous report
1,631,150
Avg daily volume
138,983
Days to cover
11.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-29Patel SnehalPurchase (P)Common Stock700USD 13.10USD 9,170SEC filing ↗
2026-07-28Patel SnehalPurchase (P)Common Stock1,500USD 13.59USD 20,385SEC filing ↗
2026-07-27Patel SnehalPurchase (P)Common Stock1,500USD 13.62USD 20,430SEC filing ↗
2026-07-24Patel SnehalPurchase (P)Common Stock1,100USD 12.88USD 14,168SEC filing ↗
2026-07-23Patel SnehalPurchase (P)Common Stock2,500USD 13.14USD 32,850SEC filing ↗
2026-01-13Patel SnehalPurchase (P)Common Stock1,800USD 29.83USD 53,694SEC filing ↗
2026-01-12Patel SnehalPurchase (P)Common Stock2,900USD 27.54USD 79,866SEC filing ↗
2025-12-31Patel SnehalPurchase (P)Common Stock4,300USD 21.36USD 91,848SEC filing ↗
2025-12-30Patel SnehalPurchase (P)Common Stock2,900USD 21.73USD 63,017SEC filing ↗
2025-12-18Patel SnehalPurchase (P)Common Stock4,100USD 12.62USD 51,742SEC filing ↗
2025-11-25Patel SnehalPurchase (P)Common Stock4,600USD 8.37USD 38,502SEC filing ↗
2025-11-07Patel SnehalPurchase (P)Common Stock10,600USD 8.43USD 89,358SEC filing ↗
2025-10-31Patel SnehalPurchase (P)Common Stock2,300USD 9.26USD 21,298SEC filing ↗
2025-04-25Patel SnehalPurchase (P)Common Stock3,600USD 9.88USD 35,568SEC filing ↗
2025-04-17Patel SnehalPurchase (P)Common Stock5,400USD 8.98USD 48,492SEC filing ↗

Form 4 evidence

13 transaction lines in the latest 365-day window; 141 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-29Patel SnehalPurchase (P)Common Stock700USD 13.10USD 9,170SEC filing ↗
2026-07-28Patel SnehalPurchase (P)Common Stock1,500USD 13.59USD 20,385SEC filing ↗
2026-07-27Patel SnehalPurchase (P)Common Stock1,500USD 13.62USD 20,430SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-29Patel SnehalPurchase (P)Common Stock700USD 13.10USD 9,170SEC filing ↗
2026-07-28Patel SnehalPurchase (P)Common Stock1,500USD 13.59USD 20,385SEC filing ↗
2026-07-27Patel SnehalPurchase (P)Common Stock1,500USD 13.62USD 20,430SEC filing ↗
2026-07-24Patel SnehalPurchase (P)Common Stock1,100USD 12.88USD 14,168SEC filing ↗
2026-07-23Patel SnehalPurchase (P)Common Stock2,500USD 13.14USD 32,850SEC filing ↗
2026-01-13Patel SnehalPurchase (P)Common Stock1,800USD 29.83USD 53,694SEC filing ↗
2026-01-12Patel SnehalPurchase (P)Common Stock2,900USD 27.54USD 79,866SEC filing ↗
2025-12-31Patel SnehalPurchase (P)Common Stock4,300USD 21.36USD 91,848SEC filing ↗
2025-12-30Patel SnehalPurchase (P)Common Stock2,900USD 21.73USD 63,017SEC filing ↗
2025-12-18Patel SnehalPurchase (P)Common Stock4,100USD 12.62USD 51,742SEC filing ↗
2025-11-25Patel SnehalPurchase (P)Common Stock4,600USD 8.37USD 38,502SEC filing ↗
2025-11-07Patel SnehalPurchase (P)Common Stock10,600USD 8.43USD 89,358SEC filing ↗
2025-10-31Patel SnehalPurchase (P)Common Stock2,300USD 9.26USD 21,298SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerGLSI
CIK0001799788
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history141 transaction lines from 2020-09-29 to 2026-07-29
122 P purchase lines · 0 S sale lines · 19 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.